

# LA GENETICA DELLE EPILESSIE

## Bibliografia

- <sup>1</sup> Anderson VE, Wilcox KJ, Rich SS et al Twin studies in epilepsy In : Beck- Mannagetta, Anderson, Doose and Janz (Eds), Genetics of the epilepsy, Springer-Verlag, Heidenberg, pp 145-155, 1989
- <sup>2</sup> Anderson VE, Rich SS, Hauser WA et al Family studies in epilepsy In : Anderson, Hauser, Leppik, Noebels and Rich (Eds), Genetic strategies in epilepsy research (Epilepsy Res , Suppl 4 ), Elsevier science Publ, pp 89-104, 1991
- <sup>3</sup> Bianchi A., Viaggi S., Chiossi E. et al Family study of epilepsy in first degree relatives: data from the Italian Episcreen study Seizure, 12 :203-210, 2003
- <sup>4</sup> Pedley TA EEG traits In : Engel and Pedley (Eds), Epilepsy : a comprehensive textbook, Lippincott-Raven Publ,pp185-196, 1997
- <sup>5</sup> Italian League Against Epilepsy Genetic Collaborative Group (A. Bianchi, coordinator) Concordance of clinical forms of epilepsy in families with several affected members Epilepsia, 34 (5): 819-826, 1993
- <sup>6</sup> Greenberg DA, Delgado-Escueta AV, Wideltitz H et al. Juvenile myoclonic epilepsy may be linked to the Bf and HLA loci on human chromosome 6. Am J Med Gen, 31: 185-192, 1988
- <sup>7</sup> Steinlein O, Mulley JC, Propping P et al A missense mutation in the neuronal nicotinic acetylcholine receptor alfa 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy Nature Genetics, 11:201-203, 1995
- <sup>7</sup> Wallace R.H., Wang D.W., Singh R. et al Febrile seizures and generalized epilepsy associated with a mutation in the Na<sup>+</sup>-channel 1 subunit gene SCN1B. Nature Genetics,19:366-370, 1998
- <sup>8</sup> Singh N.A., Charlier C., Stauffer D. et al A novel potassium channel gene, KNQ2, is mutated in an inherited epilepsy of newborns. Nature genetics,18:25-29, 1998
- <sup>9</sup> Charlier C, Singh N.A., Ryan S.G. et al A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nature genetics,18:53-55, 1998
- <sup>10</sup> Heron SE, Crossland KM, Andermann E et al Sodium-channel defects in benign familial neonatal-infantile seizures Lancet, 360 : 851-852, 2002
- <sup>11</sup> De Fusco M, Becchetti A, Patrignani A et al The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy Nature Genetics, 26 :275-276, 2000
- <sup>12</sup> Kalachikov S, Evgrafov O, Ross B et al Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nature Genet 30: 335-341, 2002
- <sup>13</sup> Marini C, Harkin LA, Wallace RH et al Childhood absence epilepsy and febrile seizures : a family with a GABA<sub>A</sub> receptor mutation Brain, 126 : 230-240, 2003
- <sup>14</sup> Cossette P, Liu L, Brisebois K et al Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy Nature Genetics 31 : 184-189, 2002
- <sup>15</sup> Suzuki T, Delgado-Escueta AV, Aguan K et al Mutations in EFHC1 cause juvenile myoclonic epilepsy Nature Genetics, 36 : 842-849, 2004
- <sup>16</sup> Haug K, Warnstedt M, Alekov AK et al Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies Nature Genetics, 33 : 527-532, 2003

- <sup>17</sup> Wallace RH, Wang DW, Singh R et al Febrile seizures and generalized epilepsy associated with a mutation in the Na<sup>+</sup>-channel beta1 subunit gene SCN1B *Nature Genetics*, 19 : 366-370, 1998
- <sup>18</sup> Escayg A, Baulac S, Moulard B et al Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2 *Nature Genetics*, 26 :275-276, 2000
- <sup>19</sup> Baulac S, Huberfeld G, Gourfinkel-An I et al First genetic evidence of GABA A receptor dysfunction in epilepsy : a mutation in the gamma2-subunit gene *Nature Genetics* 28 :46-48, 2001
- <sup>20</sup> Claes L, Del-Favero J, Ceulemans B et al De Novo Mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. *Am J Hum Genet* 68:1327-32, 2001.
- <sup>21</sup> Delgado-Escueta AV, Ganesh S, Yamakawa K Advances in the genetics of Progressive Myoclonus Epilepsy *Am J Med Genet* 106 : 129-138, 2001
- <sup>22</sup> Sisodiya SM Mechanism of antiepileptic drug resistance *Curr Opin Neurol.* 16 : 197-201, 2003

# AMILOIDOSI PRIMARIA

## Bibliografia

- <sup>1</sup> Westermark P., Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature- 2002. *Amyloid* 2002; 9-197-200.
- <sup>2</sup> Tabet JY et al. Echocardiography in elderly patients. *Press. Med.* 2004 Mar 27; 33 (6): 406-12.
- <sup>3</sup> Brychta T. et al Restrictive cardiomyopathy as a manifestation of primary amyloidosis on *Vinetr Lek.* 2004 Jan; 50 (1): 66-71.
- <sup>4</sup> Oki et al. Diagnosis of cardiac amyloidosis based on the myocardial velocity profile in the hypertrophied left ventricular wall. *On Am. J. Cardiol.* 2004 Apr 1; 93 (7): 864-9.
- <sup>5</sup> Rahman JE et al. Non invasive diagnosis of biopsy-proven cardiac amyloidosis. *On J. Am. Coll. Cardiol.* 2004 Feb 4; 43 (3): 410-5.
- <sup>6</sup> Walecki J. et al. Usefulness of <sup>1</sup>H MR spectroscopy in the evaluation of myocardial metabolism in patients with dilated idiopathic cardiomyopathy pilot study. *On Acad. Radiol.* 2003 Oct.; 10 (10): 1187-92.
- <sup>7</sup> Bonvini RF and Cmenzind E. Left ventricular hypertrophy: diagnostic pitfalls. *On Swiss Med. Wkly* 2004; 134: 289-292.
- <sup>8</sup> Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection a clinically useful test. *On Diagn. Cytopathol.* 2004 Mar; 30 (3): 178-81.
- <sup>9</sup> Koyama J et al. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. *On J. Am. Soc. Echocardiogr.* 2004 Jan; 17 (1): 36-44.
- <sup>10</sup> Palladini G et al. Association of Melphalan and high-dose dexamethasone is efficacious and well tolerated in patients with AL (primary) amyloidosis who are eligible for stem cell transplantation. *On Blood* 2004 Apr 15; 103 (8): 2936-8. Epub 2003 Dec 18.

# LA DIAGNOSI IN MEDICINA DEL LAVORO

## Note bibliografiche

- <sup>1</sup> American College of Physicians. Occupational and environmental medicine: the internist's role. *Ann Intern Med* 1990;113:974-82.
- <sup>2</sup> American College of Occupational and Environmental Medicine. Recommended library for occupational and environmental physicians. *J Occup Med* 1994;36:779-83.
- <sup>3</sup> Bond GG, Bodner KM, Sobel W, Shellenberger RJ, Flores GH. Validation of work histories obtained from interviews. *Am J Epidemiol* 1988;128:343-51.
- <sup>4</sup> Bourbonnais R, Meyer F, Theriault G. Validity of self reported work history. *Br J Ind Med* 1988;45:29-32.
- <sup>5</sup> Cullen MR, Cherniack MG, Rosenstock L. Occupational medicine. *N Engl J Med* 1990;322:594-601, 675-83.
- <sup>6</sup> Frank AL. Approach to the patient with an occupational or environmental illness. *Prim Care* 2000; 27(4):877-94.
- <sup>7</sup> Harris JS, Glass LS, Mueller KL, Genovese E; ACOEM Practice Guidelines Committee. Evidence-based clinical occupational medicine: updating the ACOEM occupational medicine practice guidelines. *Clin Occup Environ Med*. 2004 May;4(2):viii, 341-60.
- <sup>8</sup> Hirvonen A. Genetic factors in individual responses to environmental exposures. *J Occup Environ Med* 1995;37:37-43.
- <sup>9</sup> Kuschner WG, Stark P. Occupational lung disease. Part 2. Discovering the cause of diffuse parenchymal lung disease. *Postgrad Med*. 2003 Apr;113(4):81-8.
- <sup>10</sup> Landrigan PJ, Baker DB. The recognition and control of occupational disease. *JAMA* 1991;266:676-80.
- <sup>11</sup> Muzi G, Locati EH, Murgia N, Ambrosio G, Abbritti G. Evaluation of the effects of occupational noxae on the cardiovascular system. *Med Lav*. 2004 Mar-Apr;95(2):145-57.
- <sup>12</sup> Newman LS. To Be or not to Be: immunogenetics and occupational exposure. *Science* 1993;262:197-8.
- <sup>13</sup> Rosenstock L, Rest KM, Benson JA Jr, et al. Occupational and environmental medicine: meeting the growing need for clinical services. *N Engl J Med* 1991;325:924-7.
- <sup>14</sup> Van Damme K, Casteleyn L, Heseltine E, et al. Individual susceptibility and prevention of occupational diseases: scientific and ethical issues. *J Occup Environ Med* 1995;37:91-9.

# LA SILICOSI E L'INDUSTRIA ORAFA

## Note bibliografiche

- <sup>1</sup> Accattoli MP, Muzi G, Curina A, Monaco A, dell'Omo M, Murgia N, Abbritti G. Silver casting and the risk of silicosis. Proceedings International Congress on Occupational Health, Iguassu Falls, 23-28 February 2003.
- <sup>2</sup> Bodo M, Bellocchio S, Bellucci C, Balloni S, Pietrella D, Sbaraglia G, Muzi G, Lilli C, Lumare A, Dell'Omo M, Abbritti G. Silica, hyaluronate, and alveolar macrophage functional differentiation. *J Investig Med* 51, 2, 95-103, 2003.
- <sup>3</sup> Castranova V, Vallyathan V. Silicosis and Coal Workers' Pneumoconiosis. *Environ Health Perspect* 108(Supplement 4), 675-684, 2000.
- <sup>4</sup> Davis GS. Silicosis. In: Hendrick DJ, Burge PS, Beckett WS, Churg A, Occupational disorders of the lung. WS Saunders, London, 2002.
- <sup>5</sup> Finkelstein Murray M. Silica, silicosis and lung cancer: a risk assessment. *Am J Ind Med* 38, 8-18, 2000.
- <sup>6</sup> Hertzberg VS, Rosenman KD, Reilly MJ, Rice CH. Effect of occupational silica exposure on pulmonary function. *Chest* 122, 721-728, 2002.
- <sup>7</sup> Hessel PA, Gamble JF, Gee JBL, Gibbs G, Green FHY, Morgan WKC, Mossman BT. Silica, silicosis and lung cancer: a response to a recent working group report. *J Occup Environ Med* 42,7, 704-720, 2000.
- <sup>8</sup> IARC, Silica, some silicates, coal dust and para-aramid fibrils. Vol:68, 1997.
- <sup>9</sup> INAIL. Rapporto annuale 2002, INAIL 2003.
- <sup>10</sup> Occupational Safety & Health Administration (OSHA). Medical Screening/Surveillance, 2003, [www.osha.gov](http://www.osha.gov) .

# TRATTAMENTO INTEGRATO DEI TUMORI DELLA CERVICe UTERINA IN STADIO AVANZATO

## Bibliografia

- <sup>1</sup> Rose PG, Bundy BN, Watkins EB – Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer – N Engl J Med 1999 340: 1144-1153
- <sup>2</sup> Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Mangioni C, Bandoni F – Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study – J Clin Oncol 2002 20: 2908-2909

# TRATTAMENTO RADIOCHEMIOTERAPICO CONCOMITANTE NELLE NEOPLASIE DELLA CERVICE UTERINA IN STADIO AVANZATO

## Bibliografia

- <sup>1</sup> Morris M, Eifel PJ, Lu J, et al.: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. *N Engl J Med* 340 (15): 1137-43, 1999.
- <sup>2</sup> Rose PG, Bundy BN, Watkins EB, et al.: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. *N Engl J Med* 340 (15): 1144-53, 1999.
- <sup>3</sup> Keys HM, Bundy BN, Stehman FB, et al.: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N Engl J Med* 340 (15): 1154-61, 1999.
- <sup>4</sup> Whitney CW, Sause W, Bundy BN, et al.: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. *J Clin Oncol* 17 (5): 1339-48, 1999.
- <sup>5</sup> Thomas GM: Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. *N Engl J Med* 340 (15): 1198-200, 1999.
- <sup>6</sup> Pearcey R, Brundage M, Drouin P, et al.: Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. *J Clin Oncol* 20 (4): 966-72, 2002.
- <sup>7</sup> Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. *J Clin Oncol.* 2002 ;20:179-188

# TRATTAMENTO INTEGRATO NEI TUMORI POLMONARI NON A PICCOLE CELLULE IN STADIO III B

## Bibliografia

- <sup>1</sup> Perez CA, Pajak TF, Rubin P et al: Long term observations of the patterns of failure in patients with unresectable non-small cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. *Cancer* 1987; 59:1874-81.
- <sup>2</sup> Dillman RO, Seagren SL, Propert KJ et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. *N Engl J Med* 1990;323:940-45.
- <sup>3</sup> Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non Small Cell Lung Cancer Collaborative Group. *BMJ* 1995;311:899-909.
- <sup>4</sup> Dillman RO, Herndon J, Seagren SL et al: Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. *J Natl Cancer Inst* 1996;88:1210-15.
- <sup>5</sup> Cullen MH, Billingham LG, Woodroffe CM et al: Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. *J Clin Oncol* 1999; 17:3188-3194.
- <sup>6</sup> Sause WT, Scott C, Taylor S et al: Radiation Therapy Oncology Group (RTOG) 8809 and Eastern Cooperative Oncology Group (ECOG) 4588. Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. *J Natl Cancer Inst* 1995;87:198-205.
- <sup>7</sup> Schaake-Koning C, Van den Bogaert W, Dalesio O et al: Effects of concurrent cisplatin and radiotherapy on inoperable non-small-cell lung cancer. *N Engl J Med* 1992;326:524-530.
- <sup>8</sup> Furuse K, Fuluola M, Kawahra M et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. *J Clin Oncol* 1999;17:2692-2699.
- <sup>9</sup> Curran WJ, Scott C, Langer C et al: Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: initial reports of radiation therapy oncology group (RTOG) 94-10. *Proc Am Soc Clin Oncol* 2000; 19:484a
- <sup>10</sup> Vokes EE, Herndon JE, Crawford J et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study (CALGB) 94-31. *J Clin Oncol* 2002; 20:4191-4198.

# TRATTAMENTO INTEGRATO NEI TUMORI POLMONARI NON A PICCOLE CELLULE IN STADIO III B - RADIOTERAPIA

## Bibliografia

- <sup>1</sup> Tyldesley S, Boyd C, Schultze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. *Int. J. Radiat. Oncol. Biol. Phys.* 49:973-985;2001.
- <sup>2</sup> Bradley J, Govindan R, Komaki R. Lung. In: Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich R. *Principles and Practice of Radiation Oncology*, fourth edition, Lippincot Williams & Wilkins, Philadelphia, 2004, p. 1201-1243.
- <sup>3</sup> Fletcher G. Clinical dose-response curves of human malignant epithelial tumors. *Br. J. Radiol.* 46:1-12;1973.
- <sup>4</sup> Arriagada R, le Chevalier T, Quoix E, Ruffie P, de Cremoux H, Douillard J-Y, Tarayre M, Pignon J-P, Laplanche A. ASTRO Plenary : effect of chemotherapy on locally advanced non-small cell lung carcinoma : a randomized study of 353 patients. *Int. J. Radiat. Oncol. Biol. Phys.* 20:1183-1190;1991.
- <sup>5</sup> Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu J, Bosch W, Emami B. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.* 61:318-328;2005
- <sup>6</sup> Pirtoli L, Crociani M, Volterrani L, Carfagno T. New imaging resources for volume definition in radiotherapy of non small-cell lung cancer. *Atti XII Congresso Nazionale AIRO. Cagliari 13-16 X 2002*, p. 53-60.
- <sup>7</sup> Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, Seki H, Nambu Y, Tonami H, Yamamoto I. FDG PET measurement of the proliferative potential of non-small cell lung cancer. *J. Nucl. Med.* 41:85-92;2000.
- <sup>8</sup> Rasey JS, Koh W-J, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] Fluoromisonidazole: a pretherapy study of 37 patients. *Int. J. Radiat. Oncol. Biol. Phys.* 36:417-428;1996.
- <sup>9</sup> Chatziioannou AF, Cherry SR, Shao Y, Silverman RW, Meadors K, Farquhar TH, Pedarsani M, Phelps M. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. *J. Nucl. Med.* 40:1164-1175;1999.
- <sup>10</sup> Marks LB, Spencer DP, Sherouse GW, Bentel G, Clough R, Vann K, Jaszczak R, Coleman RE, Prosnitz LR. The role of three dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram. *Int. J. Radiat. Oncol. Biol. Phys.* 33:65-75;1995
- <sup>11</sup> Seppenwoolde Y, Muller S, Theuws JCM, Baas P, Belderbos JSA, Boersma LJ, Lebesque JV. Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 47:681-690;2000.
- <sup>12</sup> Burman C, Kutcher GJ, Emami B, Goiten M. Fitting of normal tissue tolerance to an analytic function. *Int. J. Radiat. Oncol. Biol. Phys.* 21:123-135;1991.
- <sup>13</sup> Byhardt RW, Martin L, Payak TF, Shin KH, Emami B, Cox JD. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC): analysis of a Radiation Therapy Oncology Group (RTOG) protocol. *Int. J. Radiat. Oncol. Biol. Phys.* 27:537-544;1993.
- <sup>14</sup> Graham MV, Purdy JA, Emami B, Harms W, Bosh W, Lockett MA, Perez CA. Clinical dose-volume his-

tograms analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). *Int. J. Radiat. Oncol. Biol. Phys.* 45:323-329;1999.

<sup>15</sup> Rosenzweig KE, Sim SE, Mychalczak B, Braban LE, Schindelheim R, Leibel SA. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 50:681-685;2001.

<sup>16</sup> Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose-escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. *Int. J. Radiat. Oncol. Biol. Phys.* 57:875-890;2003

<sup>17</sup> Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. *BMJ* 311:899-909;1995

<sup>18</sup> Curran WJ, Scott C, Langer C, Komaki R, Lee JS, Hauser S, Mosvas B, Wasserman T, Rosenthal S, Byhardt R, Sause W, Cox J. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG). *Proc. Am. Soc. Clin. Oncol.* 19:1981a;2000.

<sup>19</sup> Movsas B, Scott C, Curran W, Byhardt R, Langer C. A Quality-Adjusted Time Without Symptoms or Toxicity (QTwist) Analysis of Radiation Therapy Oncology Group (RTOG) 94-10. *Proc. Am. Soc. Clin. Oncol.* 19:1247a;2000.

<sup>20</sup> Patel AB, Edelman MJ, Kwok Y, Krasna MJ, Suntharalingam M. Predictors of acute esophagitis in patients with non-small cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. *Int. J. Radiat. Oncol. Biol. Phys.* 60:1106-1112;2004.

<sup>21</sup> Vokes EE, Herndon JE II, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIb non-small-cell lung cancer: Cancer and Leukemia Group B Study 9413. *J. Clin. Oncol.* 20:4191-4198;2002

<sup>22</sup> Trodella L, Granone P, Valente S, Margaritora S, Macis G, Cesario A, D'Angelillo RM, Valentini V, Corbo GM, Porziella V, Ramella S, Tonini G, Galetta D, Ciresa M, Vincenzi B, Cellini N. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIa-IIIb) non-small-cell lung cancer: long-term results according to downstaging. *Ann. Oncol.* 15:389-398;2004

# TRATTAMENTO RADIOCHEMIOTERAPICO DEI TUMORI POLMONARI NON A PICCOLE CELLULE (NSCLC), STADIO III B

## Bibliografia

- <sup>1</sup> B. Feragalli, L. Bonano: "Il carcinoma del polmone non microcitoma. La diagnosi precoce. Applicabilità di uno screening ". I suppl. di Tumori; Vol. 3; n° 2; S5-S8, 2004.
- <sup>2</sup> Pignom JP, Arriagada R, Idhe DC et al. " A metanalysis of thoracic radiotherapy for small cell lung cancer ". N. Engl. J. Med. 327:1618-1624,1992.
- <sup>3</sup> Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe TERRIER mj, Douillard JY, Laplanche A. "Radiotherapy alone versus combined chemotherapy and radiotherapy in non resectable non-small cell lung cancer : first analysis of a randomized trial in 353 patients ". J Natl cancer Inst. 1992 Jan 1; 84(1): 58.
- <sup>4</sup> Le Chevalier T, Arriagada R., Quoix E., Ruffie P., Martin M., Douillard JY., Taray M., Lacombe-Terrier MJ :, Laplanche A. " Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non small cell lung cancer ".Lung cancer. 1994 Mar; Suppl. 1: S239-44.
- <sup>5</sup> Juretic A, Sobat H, Samaija M. "Combined modality therapy of non small cell lung cancer ". Ann. Oncol. 1999; 10 Suppl. 6:93-8.
- <sup>6</sup> S. Novello, T. Le Chevalier:" Use of chemo-radiotherapy in locally advanced non-small cell lung cancer". European Journal of cancer 38 ( 2002) 292-299.
- <sup>7</sup> Ready N. E, Vokes "Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small lung cancer ". Lung cancer (2003) 42,65-69.
- <sup>8</sup> Zatloukal P. ed aa. "Concurrent versus sequential chemo-radiotherapy with cisplatin and vinorelbine in locally advanced non small cell lung cancer: a randomized study".Lung cancer (2004) 46,87-98.
- <sup>9</sup> T. Le Chevalier, G. Scagliotti, R. Natale, S. Danson e al. "Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non small cell cancre: a meta-analysis of survival outcomes ". Lung cancer October 2005; 47, 69-80 Elsevier.

# LE NEOPLASIE DEL CANALE ANALE

## Bibliografia

- <sup>1</sup> Boman BM, Moertel CG, O'Connell MJ, Scott M, Weiland LH, Beart RW, Gunderson LL, Spencer RJ. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. *Cancer*. 1984; 54:114-25.
- <sup>2</sup> Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Houry S, Gallot D, Parc R, Huang R, Qu SH, Huart J, Pene F, Schlienger M. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. *Int J Radiat Oncol Biol Phys*. 2003;56:1259-73.
- <sup>3</sup> Nigro ND, Vaitkevicius VK, Considine B. Combined Therapy for cancer of the anal canal: A preliminary report. *Dis Colon Rectum*, 1974; 17: 354-6.
- <sup>4</sup> UKCCCR Anal Cancer Trial Working Party: Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. *Lancet*, 1996; 348: 1049-54.
- <sup>5</sup> Bartelink H, Roelofs F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol*. 1997;15:2040-9.
- <sup>6</sup> Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. *J Clin Oncol*. 1996;14:2527-39.
- <sup>7</sup> Hung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, Feig B, Skibber J, Janjan N. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. *Cancer*. 2003;97:1195-202.
- <sup>8</sup> Wong CS, Tsang RW, Cummings BJ, Fyles AW, Couture J, Brierley JD, Pintilie M. Proliferation parameters in epidermoid carcinomas of the anal canal. *Radiother Oncol*. 2000;56:349-53.
- <sup>9</sup> John M, Flam M, Palma N. Ten-year results of chemoradiation for anal cancer: focus on late morbidity. *Int J Radiat Oncol Biol Phys*. 1996;34: 65-9.
- <sup>10</sup> Weber DC, Kurtz JM, Allal AS. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. *Int J Radiat Oncol Biol Phys*. 2001;50:675-80.
- <sup>11</sup> Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF. Time-dose considerations in the treatment of anal cancer. *Int J Radiat Oncol Biol Phys*. 1997;39:651-7.
- <sup>12</sup> Vuong T, Devic S, Belliveau P, Muanza T, Hegyi G. Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. *Int J Radiat Oncol Biol Phys*. 2003;56:823-31.
- <sup>13</sup> Longo WE, Vernava AM 3rd, Wade TP, Coplin MA, Virgo KS, Johnson FE. Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. *Ann Surg*. 1994;220:40-9.

# **RADIOCHEMIOTERAPIA CONCOMITANTE NEL TRATTAMENTO DEL CARCINOMA DEL CANALE ANALE: VALUTAZIONE DI OUTCOME E TOSSICITÀ IN 30 CASI TRATTATI CONSECUTIVAMENTE**

## **Bibliografia**

- <sup>1</sup> Cummings BJ: The Role of Radiation Therapy With 5-Fluorouracil in Anal Cancer. *Semin Radiat Oncol* 7 (4): 306-312, 1997.
- <sup>2</sup> Leichman L, Nigro N, Vaitkevicius VK, et al.: Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. *Am J Med* 78 (2): 211-5, 1985.
- <sup>3</sup> Sischy B: The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum. *Int J Radiat Oncol Biol Phys* 11 (9): 1587-93, 1985.
- <sup>4</sup> Sischy B, Doggett RL, Krall JM, et al.: Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. *J Natl Cancer Inst* 81 (11): 850-6, 1989.
- <sup>5</sup> Cummings BJ: Anal cancer. *Int J Radiat Oncol Biol Phys* 19 (5): 1309-15, 1990.
- <sup>6</sup> Zucali R, Doci R, Bombelli L: Combined chemotherapy--radiotherapy of anal cancer. *Int J Radiat Oncol Biol Phys* 19 (5): 1221-3, 1990.
- <sup>7</sup> Fuchshuber PR, Rodriguez-Bigas M, Weber T, et al.: Anal canal and perianal epidermoid cancers. *J Am Coll Surg* 185 (5): 494-505, 1997.
- <sup>8</sup> Boman BM, Moertel CG, O'Connell MJ, et al.: Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. *Cancer* 54 (1): 114-25, 1984.
- <sup>9</sup> Flam M, John M, Pajak TF, et al.: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. *J Clin Oncol* 14 (9): 2527-39, 1996.